BurtonLasaterScottMD

PubMed

• 363 citations
  Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.
  Todd L. Edwards, William K. Scott, Cherylyn Almonte, Amber Burt, Eric Powell
  Annals of Human Genetics. 2010-03-01
• 125 citations
  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
  Michael A. Hauser, Yi-Ju Li, Hong Xu, Maher A. Noureddine, Yujun S. Shao
  Archives of Neurology. 2005-06-01
• 435 citations
  Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
  Joelle M. van der Walt, Kristin K. Nicodemus, Eden R. Martin, William K. Scott, Martha Nance
  American Journal of Human Genetics. 2003-04-01

Journal Articles

• Linkage of familial essential tremor to chromosome 5q35  
  Hicks JE, Konidari I, Scott BL, Stajich JM, Ashley-Koch AE, Gilbert JR, Scott WK, Mov. Disord, 1/1/2016
• Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind randonised trial  
  NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators, Lancet Neurol, 1/1/2015
• Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience  
  Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators, JAMA Neurol, 1/1/2014
• Natural history of Huntington Disease  
  Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AFD, Biglan KM, Shoulson I, for the Huntington Study Group COHORT Investigators, JAMA Neurol, 1/1/2013
• Design innovations and baseline findings in a long-term Parkinson�s trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson�...  
  Elm, JJ, The NINDS NET-PD Investigators, Mov. Disord., 1/1/2012
• Auditory-perceptual analysis of dysarthria in bilateral striatopallidodentate calcinosis (Fahr�s disease)  
  Jacks A, Haley KL, Scott BL, Jones H, J Med Speech Lang Pathol., 1/1/2012
• Meta-analysis of Parkinson�s disease: identification of a novel locus, RIT2  
  Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Donheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER..., Ann Neurol., 1/1/2012
• Predictors of time to requiring dopaminergic treatment in 2 Parkinson�s disease cohorts  
  Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE on behalf of the Parkinson Study Group DATAOP and PRECEPT Investigators, Mov Disord, 1/1/2011
• A long-term study of istradefylline in subjects with fluctuating Parkinson�s disease  
  Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM, Istradefylline 6002-US-007 Study Group, Parkinsonism Relat Disord, 1/1/2011
• Integrated behavior therapy in the treatment of complicated Tourette�s disorder and its comorbidities  
  Bryson WJ, Edwards CL, Sommer DB, Scott BL, Clin. Case Studies, 1/1/2010
• Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease  
  Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines ..., Ann Hum Genet., 1/1/2010
• Impulse control disorders arising in 3 patients treated with rotigotine  
  Wingo TS, Evatt M, Scott B, Freeman A, Stacy M, Clin Neuropharm, 1/1/2009
• Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson�s disease: a randomized, double-blind, non-inferiority crossover study  
  Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Curr. Med. Res. Opin., 1/1/2008
• Pesticide exposure and risk of Parkinson�s disease: a family-based case-control study  
  Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK, BMC Neurology, 1/1/2008
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease  
  The NINDS NET-PD Investigators, Neurology, 1/1/2007
• Parkinson�s disease � A form of �Idiopathic parkinsonism�  
  Scott BL, Wake Co. Physician, 1/1/2007
• Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease  
  Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK, Arch. Neurol, 1/1/2007
• A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease  
  The NINDS NET-PD Investigators, Neurology, 1/1/2006
• NOS2A and the modulating effect of cigarette smoking in Parkinson�s disease  
  Hancock DB, Martin ER, Fujiwara K, Stacy MA, Scott BL, Stajich JM, Jewett R, Li YJ, Hauser MA, Vance JM, Scott WK, Ann. Neurology, 1/1/2006
• Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson Disease  
  Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Woo..., Ann. Neurol, 1/1/2006
• Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism  
  Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, Scherzer CR, Jensen RV, McLaurin AC, Gibson JR, Scott BL, Jewett RM, Stenger JE, Schmechel DE, Hulette CM, ..., Arch. Neurol., 1/1/2005
• Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra  
  Noureddine MA, Li YJ, van der Walt JM, Walters R, Jewett RM, Xu H, Wang T, Walter JW. Scott BL, Hulette C, Schmechel D, Stenger JE, Dietrich F, Vance JM, Hauser MA, Mov. Disord, 1/1/2005
• Family-based case control study of cigarette smoking and Parkinson disease  
  Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM, Neurology, 1/1/2005
• Fibroblast Growth Factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease  
  Van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK, McKay R, Zhang F, Stajich JM, Fujiwara K, Scott BL, Pericak-Vance MA, Vance JM, Martin ER, Am. J. Human Genet., 1/1/2004
• A case of combined orthostatic tremor and primary gait ignition failure  
  Myers BH, Scott BL, Clin. Neurol. Neurosurg, 1/1/2003
• Join now to see all

Books/Book Chapters

• The American Psychiatric Publishing Textbook of Geriatric Psychiatry 
  Chapter: Movement disorders 
  Page 231.0 - 240.0Scott BLEditors: Blazer DG, Steffens DC, Busse E.American Psychiatric Publishing, Arlington, VAEdition 3rd,2004
• Neuromethods 
  Chapter: Quantitative analysis of acyl group composition of brain phospholipids, neutral lipids, and free fatty acids. 
  Page 83.0 - 110.0Marcheselli VL, Scott BL, Reddy TS, Bazan NGEditors: Boulton AA, Baker GB, Horrocks LA.Humana Press, Clifton, NJ1987
• Neuromethods 
  Chapter: Quantitative analysis of acyl group composition of brain phospholipids, neutral lipids, and free fatty acids 
  Marcheselli VL, Scott BL, Reddy TS, Bazan NGEditors: Boulton AA, Baker GB, Horrocks LA.Humana Press, Clifton, NJ1987

Abstracts/Posters

• Impulse control disorders arising in three patients treated with rotigotine. Impulse Control Disorders in Parkinson�s Disease Abstract Supplement.
  Wingo TS, Evatt M, Scott B, Freeman A, Stacy M, Mov. Disord., 1/1/2008
• Safety and Tolerability of Istradefylline (KW-6002) in Parkinson�s Disease With Motor Response Complications: Results of the KW-6002-US-018 Study.
  Pourcher E and the 6002-US-018 Clinical Investigator Group, Congress of Parkinson�s Disease and Movement Disorders, Kyoto, Japan, 1/1/2006
• Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson�s disease.
  Stocchi F, Hersh BP, Earl NL, Scott BL, Mov. Disord, 1/1/2006
• Istradefylline for the Treatment of Motor Response Complications on Levodopa in PD patients: Results of the KW-6002-US-018 Study Focusing on Functional and Motor Impro...
  Fernandez HH and the 6002-US-018, 10th International Congress of Parkinson�s Disease and Movement Disorders, Kyoto, Japan, 1/1/2006
• Efficacy of Istradefylline in Parkinson�s Disease Patients Treated With Levodopa With Motor Response Complications: Results of the KW-6002-US-018 Study
  Guttman M and the 6002 US-018 Clinical Investigator Group, 10th International Congress of Parkinson�s Disease and Movement Disorders., Kyoto, Japan, 1/1/2006
• Pesticide use and risk of Parkinson disease: A family-based case-control study.
  Scott WK, Zhang L, Stajich JM, Scott BL, Stacy MA, Vance JM, Mov. Disord., 1/1/2004
• Defining the linkage disequilibrium region containing the Tau gene and identifying haplotype tagging polymorphisms.
  Oliveira SA, Martin ER, Scott WK, Zhang F, Stajich JM, Middleton LT, Roses AD, Scott BL, Fujiwara K, Pericak-Vance MA, Vance JM, Am. J. Human. Genet., 1/1/2003
• Genomic convergence: Identification of candidate genes for Parkinson Disease (PD) using genetic linkage and gene expression in the substantia nigra.
  Hauser MA, Noureddine M, Walter JW, Walters RW, Hulette CM, Schmechel DE, Bembe ML, Stajich JM, Xu H, Martin ER, Scott BL, Stenger J, Li YJ, Jensen R, Scherzer C, Gull..., Am. J. Human Genet., 1/1/2003
• Characterization of Tau association with Parkinson disease.
  Oliveira SA, Zhang FY, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Sm..., Ann. Neurol, 1/1/2003
• Location of common age-at-onset genes in Alzheimer and Parkinson diseases.
  Li YJ, Scott WK, Hedges DK, Zhang FY, Gaskell PC, Stajich JM, Saunders AM, Scott BL, Schemechel DE, Welsh-Bohmer KA, Conneally PM, Gilbert JR, Vance JM, Pericak-Vance ..., Neurobiol. Aging, 1/1/2002
• Identification of candidate genes for Parkinson disease (PD) by the convergence of genetic linkage and association data with gene expression in the substantia nigra.
  Hauser MA, Walter JW, Walters RW, Maready M, Takeuchi S, Segars WP, Hulette CM, Schmechel DE, Bernba ML, Stajich JM, Hauser ER, Martin E, Scott BL, Stenger J, Li YJ, B..., Am. J. Human Genet, 1/1/2002
• Complete genomic screen in familial Parkinson disease.
  Scott WK, Stajich JM, Scott BL, Rogala AR, Booze MW, Ribble RC, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J..., Neurology, 1/1/2001
• Complete genomic screen in idiopathic Parkinson disease
  Scott WK, Stajich JM, Scott BL, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FH, Goetz CG, Small GW, Mastaglia F..., Am. J. Human Genet., 1/1/2001
• Validity of the CS-PFP as a measure of physical functional capacity of those in early/mid-stage Parkinson�s disease
  Schenkman M, Cutson TC, Kuchibhatia M, Scott BL, Cress ME, Gerontologist, 1/1/2001
• Parkin mutations and idiopathic Parkinson disease (PD).
  Scott WK, Rogala AR, Rampersaud E, Stajich JM, Nance MA, Watts RL, Hubble JP, Scott BL, Haines JL, Koller WC, Stern MB, Hiner BC, Jankovic J, Allen FH, Goetz CG, Small..., Am J Human Genet, 1/1/2000
• Exacerbation of stuttering after pallidotomy for Parkinson�s disease.
  Scott BL, Hurwitz B, 6th National Parkinson Foundation International Symposium on Parkinson�s Disease Research., Miami FL, 1/1/1999
• Parkinson�s Disease:Clinical Features in Sibships
  Hubble JP, Weeks CC, Nance M, Watts RL, Koller WC, Stern MB, Colcher A, Ondo W, Jankovic J, Goetz C, Pappart E, Scott WK, Stajich JM, Scott BL, Vance JM, Pericak-Vance MA, Neurology, 1/1/1999
• Exclusion of the alpha-synuclein gene as a major genetic risk factor in idiopathic Parkinson disease (PD).
  Scott WK, Yamaoka LH, Stajich JM, Speer MC, Scott BL, Nance M, Hubble J, Watts RL, Koller W, Jankovic J, Ondo W, Stern MB, Colcher A, Hiner BC, Allen FH, Goetz C, Papp..., Neurology, 1/1/1998
• The alpha-synuclein gene is not a major risk factor in familial Parkinson Disease (PD).
  Yamaoka LH, Scott WK, Stajich JM, Scott BL, Vance JM, Roses AD, Pericak-Vance MA, Annual Meeting of the American Society of Human Genetics., 1/1/1998
• Apolipoprotein E and neural survival.
  Matthew WD, Guyton JR, Scott BL, Strittmatter WJ, Exper Neurol, 1/1/1998
• Apolipoprotein E and Microtubule Dynamics
  Strittmatter WJ, Scott B, DeSerrano V, Roses AD., Keystone Conference, 1/1/1997
• Sumatriptan in the treatment of essential palatal myoclonus.
  Scott BL, Evans RW, Jankovic J, Neurology, 1/1/1996
• Delayed-onset progressive movement disorders after static brain lesions.
  Scott BL, Jankovic J, Neurology, 1/1/1995
• Polyunsaturated fatty acids in retinal development
  Scott BL, Bazan NG, American Oil Chemists Society meeting on Lipid Oxidation, Biloxi, MS, 1/1/1987
• Selective accumulation of docosahexaenoic acid (DHA) in dissociated rod photoreceptor cells during mouse postnatal development
  Scott BL, Moises J, Lolley RN, Bazan NG, Suppl Invest Ophthalmol Vis Sci, 1/1/1987
• Join now to see all

Lectures

• Parkinson�s Disease: Clinical Features 
  1/1/2009
• Movement Disorders Patients 
  1/5./2010
• Making a Difference: Results of Studies in the Area 
  Marriott at RTP - 1/30/2011
• Overview & Treatment of PD 
  Durham NC - 1/12/2010
• Clinical Trials in PD 
  Burlington NC - 1/5./2010
• Small Group Case Presentations, Non-Motor Complications 
  Duke Univ Med Ctr - 1/29/2010
• Managing Non-Motor Symptoms in PD 
  Burlington NC - 1/20/2010
• Long-Term Care of PD. Caring in the Carolinas 
  Charlotte NC - 1/2./2010
• Maximizing Discussions With Your Physician: A Caregiver�s Perspective Workshop 
  HDSA, Raleigh NC - 1/25/2010
• Medications for Early/Mid Stage HD Workshop 
  Raleigh NC - 1/25/2010
• What the Future Holds: New Studies and How You Can Play a Role 
  Marriott at RTP - 1/30/2011
• DBS in Movement Disorders 
  1/20/2009
• PD & the Use of Deep Brain Stimulation 
  1/14/2009
• Treatment of Parkinson�s Disease 
  1/25/2009
• Current Approaches in Treating Parkinson�s Disease 
  Myrtle Beach, SC - 1/11/2009
• Tetrabenazine & Clinical Trials 
  1/27/2009
• Brain 
  Durham NC - 1/3./2009
• PD and Parkinson�s Plus Syndromes 
  1/25/2009
• Parkinson's Disease 
  The Forest at Duke Assembly Hall - 1/1./2011
• RNA Interference in Neurodegenerative Diseases 
  1/11/2012
• Dopamine Dysregulation Syndrome & Impulse Control Disorders 
  The Manor Village at Preston, Cary, NC - 1/9./2012
• Huntington�s Disease, Behavioral Aspects. 
  1/20/2013
• Medical Management of PD 
  1/10/2013
• Complications of Dopaminergic Therapy 
  1/10/2013
• Painful Legs-Moving Toes � and Painful Medical Records 
  1/16/2013
• Join now to see all

Other

• Ph.D. Thesis: The Three Dimensional Structure of Visual Pigment from Bullfrog Disk Membranes. 
  
  1/1/1984